Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$19.33 +3.4%	$18.81	$10.21 ▼ $25.67	$4.46B	0.38	2.30 million shs	2.47 million shs
KRYS Krystal Biotech	$156.98 +2.0%	$140.83	$122.80 ▼ $207.84	$4.45B	0.7	279,487 shs	571,859 shs
MTSR Metsera	$34.89 +5.8%	$32.59	$12.30 ▼ $47.40	$3.47B	N/A	1.03 million shs	2.06 million shs
RCUS Arcus Biosciences	$9.16 +0.3%	$9.13	$6.50 ▼ $18.98	$966.73M	0.89	701,151 shs	805,025 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.37%	+7.33%	+6.56%	-17.81%	+57.41%
KRYS Krystal Biotech	+2.02%	+6.35%	+11.06%	-5.52%	-24.70%
MTSR Metsera	+5.76%	-13.79%	+20.89%	+36.02%	+3,488,999,900.00%
RCUS Arcus Biosciences	+0.87%	-10.28%	+6.64%	+0.44%	-44.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.2926 of 5 stars	3.7	3.0	0.0	0.0	3.8	2.5	3.1
KRYS Krystal Biotech	4.8885 of 5 stars	4.5	2.0	0.0	4.7	3.2	3.3	1.9
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	2.1528 of 5 stars	3.4	3.0	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	43.13% Upside
KRYS Krystal Biotech	3.00	Buy	$211.33	34.62% Upside
MTSR Metsera	3.00	Buy	$55.00	57.64% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	132.38% Upside

Current Analyst Ratings Breakdown

Latest RCUS, ADMA, KRYS, and MTSR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/25/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
7/25/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00
7/22/2025	KRYS Krystal Biotech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$193.00 ➝ $192.00
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.82	$0.56 per share	34.55	$1.48 per share	13.06
KRYS Krystal Biotech	$290.52M	15.62	$4.73 per share	33.18	$32.90 per share	4.77
MTSR Metsera	N/A	N/A	N/A	N/A	$4.28 per share	N/A
RCUS Arcus Biosciences	$258M	3.76	N/A	N/A	$5.30 per share	1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	22.74	28.01	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	37.74	15.57	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/6/2025 (Estimated)

Latest RCUS, ADMA, KRYS, and MTSR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	$121.77 million	N/A
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	N/A	N/A	N/A	$32.86 million	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
7/28/2025	Q2 2025	MTSR Metsera	N/A	-$0.66	N/A	-$0.66	N/A	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
KRYS Krystal Biotech	N/A	9.65	9.27
MTSR Metsera	N/A	5.26	6.55
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
KRYS Krystal Biotech	86.29%
MTSR Metsera	N/A
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
KRYS Krystal Biotech	13.70%
MTSR Metsera	N/A
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

RCUS, ADMA, KRYS, and MTSR Headlines

Recent News About These Companies

Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA

July 31 at 12:01 AM | msn.com

Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday

July 31 at 10:49 AM | marketbeat.com

Y Intercept Hong Kong Ltd Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)

July 31 at 3:36 AM | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Acquired by GSA Capital Partners LLP

July 30 at 4:19 AM | marketbeat.com

Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications

July 24, 2025 | msn.com

Arcus Biosciences Announces New Employment Inducement Grants

July 24, 2025 | businesswire.com

Precision BioSciences shares climb after FDA grants orphan drug status

July 23, 2025 | msn.com

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD

July 23, 2025 | contractpharma.comC

Precision BioSciences stock rises after FDA grants orphan drug status

July 23, 2025 | investing.com

Principal Financial Group Inc. Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

July 19, 2025 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of "Moderate Buy" by Analysts

July 18, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Shares Down 4.6% - Here's What Happened

July 15, 2025 | marketbeat.com

Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer

July 15, 2025 | pharmabiz.comP

Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For ... - Nasdaq

July 12, 2025 | nasdaq.com

Arcus Biosciences’ cancer drug gets orphan drug status

July 11, 2025 | msn.com

Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances

July 11, 2025 | appliedclinicaltrialsonline.comA

Arcus’ Quemliclustat Receives Orphan Drug Designation

July 11, 2025 | contractpharma.comC

Arcus Biosciences' Pancreatic Cancer Treatment Gets Orphan Drug Status

July 11, 2025 | marketwatch.com

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 11, 2025 | finance.yahoo.com

Arcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's Why

July 10, 2025 | marketbeat.com

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 10, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, ADMA, KRYS, and MTSR Company Descriptions

ADMA Biologics NASDAQ:ADMA

$19.33 +0.63 (+3.37%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$19.48 +0.16 (+0.80%)

As of 08/1/2025 07:51 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Krystal Biotech NASDAQ:KRYS

$156.98 +3.11 (+2.02%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$159.00 +2.02 (+1.29%)

As of 08/1/2025 07:55 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Metsera NASDAQ:MTSR

$34.89 +1.90 (+5.76%)

As of 08/1/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Arcus Biosciences NYSE:RCUS

$9.16 +0.03 (+0.33%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$8.93 -0.23 (-2.51%)

As of 08/1/2025 06:48 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time